JOP20190157A1 - مستقبل2 للمركب الترابطي المسبب تلاشي خلايا مضاد tnf ثنائية النوعية و جزيئات ربط مضاد كادهيرن 17 لعلاج السرطان - Google Patents

مستقبل2 للمركب الترابطي المسبب تلاشي خلايا مضاد tnf ثنائية النوعية و جزيئات ربط مضاد كادهيرن 17 لعلاج السرطان

Info

Publication number
JOP20190157A1
JOP20190157A1 JOP/2019/0157A JOP20190157A JOP20190157A1 JO P20190157 A1 JOP20190157 A1 JO P20190157A1 JO P20190157 A JOP20190157 A JO P20190157A JO P20190157 A1 JOP20190157 A1 JO P20190157A1
Authority
JO
Jordan
Prior art keywords
cadherin
tnf
cancer
treatment
binding molecules
Prior art date
Application number
JOP/2019/0157A
Other languages
English (en)
Inventor
Saurabh Sen
Abdulsalam Shaaban
Timothy Fenn
Jason Ho
Vladimir Voynov
Andreas Wernitznig
Rajkumar Ganesan
Juan Manuel Garcia-Martinez
Ertan Eryilmaz
Klaus-Peter Kuenkele
Christian Koessl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17155973.5A external-priority patent/EP3360898A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of JOP20190157A1 publication Critical patent/JOP20190157A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي بجزيئات رابطة والتي ترتبط تحديداً بالمستقبل 2 للمركب الترابطي الذي يحث الموت المبرمج للخلية المرتبطة بـ TNF (TRAILR2) وكادهيرين -17 (CDH17) واستخدامهما في الطب والتركيبات الصيدلانية التي تحتوي عليهما وأيضا طرق استخدامهما في شكل عوامل لمعالجة و/أو الوقاية من السرطان. الشكل 3
JOP/2019/0157A 2016-12-22 2017-06-16 مستقبل2 للمركب الترابطي المسبب تلاشي خلايا مضاد tnf ثنائية النوعية و جزيئات ربط مضاد كادهيرن 17 لعلاج السرطان JOP20190157A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437770P 2016-12-22 2016-12-22
EP17155973.5A EP3360898A1 (en) 2017-02-14 2017-02-14 Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer

Publications (1)

Publication Number Publication Date
JOP20190157A1 true JOP20190157A1 (ar) 2019-06-23

Family

ID=61157152

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0157A JOP20190157A1 (ar) 2016-12-22 2017-06-16 مستقبل2 للمركب الترابطي المسبب تلاشي خلايا مضاد tnf ثنائية النوعية و جزيئات ربط مضاد كادهيرن 17 لعلاج السرطان

Country Status (6)

Country Link
US (1) US20240150480A1 (ar)
JP (1) JP2022174194A (ar)
CL (1) CL2019001684A1 (ar)
IL (1) IL267431A (ar)
JO (1) JOP20190157A1 (ar)
PH (1) PH12019501386A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026046327A1 (en) * 2024-08-29 2026-03-05 Utc Therapeutics (Shanghai) Co., Ltd. Cdh17 targetting antibodies, chimeric antigen receptors, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ616382A (en) * 2009-04-20 2015-04-24 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17

Also Published As

Publication number Publication date
PH12019501386A1 (en) 2020-02-10
JP2022174194A (ja) 2022-11-22
US20240150480A1 (en) 2024-05-09
CL2019001684A1 (es) 2019-11-22
IL267431A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
WO2018115231A3 (en) Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MX2025009223A (es) Agentes de union a clec9a y su uso
EP4417263A3 (en) Cd3 binding antibodies
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MY205850A (en) Proteins binding bcma, nkg2d and cd16
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
MX2020004476A (es) Compuestos piridinicos de pladienolida y metodos de uso.
TW201613901A (en) New compounds
PH12016502607A1 (en) Functionalised and substituted indoles as anti-cancer agents
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2016013029A (es) Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
EA201591925A1 (ru) Терапевтические композиции и их применение
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2016014559A (es) Compuestos para el tratamiento de cancer.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
PH12016501393B1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
WO2016087932A3 (en) Macromolecular transition metal complexes for treatment of cancer and process for their preparation
PH12019501386A1 (en) Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MX2017008475A (es) Novedoso anticuerpo humanizado adam17.
MY182809A (en) Compositions for the treatment of kidney and/or liver disease